Pembrolizumab and atezolizumab (anti–PD-L1) are both approved as first-line therapies in combination with platinum-based chemotherapy and other therapies for certain patient populations with metastatic NSCLC, although atezolizumab approval with platinum-doublet chemotherapy is limited to non-squamous histology2,4,5. The gene discussed is CD274; the disease is non-small cell lung carcinoma.